Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)–based mutagenesis screen: high efficacy of drug combinations

BMS-354825 (dasatinib) and AMN107 (nilotinib) are potent alternate Abl inhibitors with activity against many imatinib mesylate–resistant BCR-ABL kinase domain (KD) mutants, except T315I. We used N-ethyl-N-nitrosourea (ENU)–exposed Ba/F3-p210(BCR-ABL) cells to compare incidence and types of KD mutant...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Bradeen, Heather A., Eide, Christopher A., O'Hare, Thomas, Johnson, Kara J., Willis, Stephanie G., Lee, Francis Y., Druker, Brian J., Deininger, Michael W.
Natura: Artigo
Lingua:Inglês
Pubblicazione: The American Society of Hematology 2006
Soggetti:
Neoplasia
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC1895563/
https://ncbi.nlm.nih.gov/pubmed/16772610
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2006-02-004580
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi